AZN vs PTGX
As of Sep 20, 2026, Astrazeneca (AZN) scores 5.0/10 and Protagonist Therapeutics (PTGX) 5.3/10 on AlphaStocks' five-model composite, so PTGX scores higher. AZN trades 14% below its model fair value.
AZN
ASTRAZENECA PLC
5.0
Consider Buy
$166.29
PTGX
Protagonist Therapeutics, Inc
5.3
Consider Buy
$142.93
AZN vs PTGX: Which is the Better Investment?
ASTRAZENECA PLC (AZN) scores 5.0/10 while Protagonist Therapeutics, Inc (PTGX) scores 5.3/10 on AlphaStocks' composite model. Protagonist Therapeutics, Inc has the higher composite rating of Consider Buy.
This comparison is algorithmically generated and is not financial advice.
| Metric | AZN | PTGX |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 5.0/10 | 5.3/10▲ |
| Rating | Consider Buy | Consider Buy▲ |
| Price | $166.29 | $142.93 |
| P/E Ratio | 25.4 | — |
| ROE | 21.9%▲ | -12.1% |
| Market Cap | $260B | $10B |
| Fair Value | $192.63 | — |
| Dividend Yield | 1.9% | — |
| Sector Rank | #111 of 168 | #87 of 168▲ |
| Model Verdicts | ||
| Piotroski | Strong▲ | Neutral |
| Buffett | Strong▲ | Limited Data |
| Graham | Caution | Caution |
| Lynch | Neutral▲ | Limited Data |
| Greenblatt | Neutral▲ | Limited Data |
Related comparisons
AZN vs PTGX: Which Stock Scores Higher?
ASTRAZENECA PLC (AZN) and Protagonist Therapeutics, Inc (PTGX) are both in the Health Care sector. PTGX currently leads with a composite score of 5.3/10 (Consider Buy) compared to AZN's 5.0/10 (Consider Buy).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer